Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: PAL who wrote (3058)	12/2/1997 11:29:00 AM
From: Oliver & Co	Read Replies (2) \| Respond to of 6136

It is a jungle out there. I may be wrong, but it seems to me that this may work out very well for them. If you read the press release closely, there may be more behind it: ====================================================================== "The move to discontine development of Thymitaq comes on the basis of Agouron's interim analysis of results from phase II/III trials of the drug and in order to concentrate available resources on development of two earlier-stage anti-cancer agents that the company believes have greater commercial potential, the company said in a statement. The discontinuation of the cancer collaboration does not affect a separate agreement under which Roche will market Agouron's HIV protease inhibitor in certain international territories, the company said". With the end of the cancer-drug collaboration, Roche will make a final payment to Agouron; and Agouron will immediately regain all marketing rights to its anti-cancer drugs previously within the scope of the collaboration". ---------------------------------------------------------------------- I think that with the success of Viracept, the revenue that it will bring, Agouron does much better without a partner. They no longer need anybody to bankroll any developments. By doing this, at this time, they get rid of Roche, and can market the other drugs on their own. If my info is right, their MMPI will be a blockbuster, Why would I share my gains?. Besides the Rhinovirus PI is around the corner. JLL